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EnterochelinKidney damage induces the expression of a myriad of proteins in the serum and in the urine. The function of
these proteins in the sequence of damage and repair is now being studied in genetic models and by novel im-
aging techniques. One of the most intensely expressed proteins is lipocalin2, also called NGAL or Siderocalin.
While this protein has been best studied by clinical scientists, only a few labs study its underlying metabolism
and function in tissue damage. Structure–function studies, imaging studies and clinical studies have revealed
that NGAL-Siderocalin is an endogenous antimicrobial with iron scavenging activity. This review discusses
the “iron problem” of kidney damage, the tight linkage between kidney damage and NGAL-Siderocalin ex-
pression and the potential roles that NGAL-Siderocalin may serve in the defense of the urogenital system.
This article is part of a Special Issue entitled: Cell Biology of Metals.
© 2012 Published by Elsevier B.V.1. Iron and kidney disease
Changes in iron distribution have been documented in both acute
kidney injury (AKI) and chronic kidney diseases (CKD). Kidney iron
and urine iron increase in CKD due to glomerular dysfunction [1–3]
which leaks transferrin and other serum proteins into the ﬁltrate,
which induce secondary tubular damage [4]. Iron appears in the urine
from hemoglobin and myoglobin extravasation [5] and from damaged
tubular cells as a result of chemotherapy (cisplatin [6]; doxorubicin
[7]), ischemia–reperfusion injury [8,9] and transplant ischemia [10] as
well as other forms of AKI [9,11–15]. In each case, “catalytic iron” is
found in the urine and blood, and oxidized lipids are well documented.
Preloading animals with iron [14] worsened these diseases and con-
versely chelating iron with desferroxamine (DFO), blunted the damage
[6,16,13,17–19]. Iron catalyzed damage is thought to be one of the ear-
liest events in kidney dysfunction and is likely to be important in other
organs aswell, including the heart [20] where the siderophore chelator,
carboxymycobactinwas said to be protective. “Ferriuria”may also stim-
ulate urinary tract infections which could result in endotoxemia and
profound ischemic damage. These data raise many questions con-
cerning the sources, mechanisms of trafﬁcking and recycling of iron in
tissue damage. It is also possible that iron release is not regulated
whatsoever.
In normal conditions, transferrin (Tf) regulates iron delivery in cir-
culation by solubilizing ferric iron (which is otherwise entirely insol-
uble above pH4; Ksp:10−10 M–10−18 M) [21] and delivering iron toiology of Metals.
+1 212 305 3475.
sevier B.V.cells via the TfR1. Yet, whether Tf-TfR1 participates in all forms of
iron transport in all extracellular spaces including the recovery of
iron in tissue damage remains to be seen. In fact, non-transferrin
mechanisms must be active under speciﬁc circumstances, as demon-
strated by a number of examples, including the hypomorphic alleles
of Tfhpx/hpx which are born iron overloaded [22–26], Tfr1 knockouts
[27] which can still initiate organogenesis, and GFP-Tfr1−/−+Tfr1+/+
embryonic chimeras [28–30] which demonstrate GFP-Tfr1−/− cells ma-
turing essentially into every component of the kidney, without the abil-
ity to capture iron from Tf. In sum, while the mechanisms of Tf-iron
chelation and donation are established, there are speciﬁc instances
which suggest non-transferrin molecules must play a role, but most of
these remain to be discovered.
In this brief review, we have examined the biology of the gene
lipocalin2, known in tissue damage studies as “NGAL” and for its cap-
ture of siderophores, as “Siderocalin (Scn)”. NGAL-Scn protein has
been intensely studied by clinical scientists, but few labs have evalu-
ated its basic biology.
2. NGAL-Scn: baseline expression
Biological ﬂuids contain very low levels of NGAL-Scn protein at
steady state level. Serum contains approximately 20 ng/ml NGAL-
Scn which is probably derived from neutrophils and from limited ex-
pression in liver, spleen and kidney [31]. Renal clearance is a major
regulator of this steady state level, because circulating NGAL-Scn un-
dergoes glomerular ﬁltration due to its low molecular weight (23–
25 kDa) andpositive charge (pI>7.4). Theoretically, the kidney process-
es 3.4–4 mgNGAL-Scn per day (20 ng/ml×120–140 ml/min glomerular
ﬁltration rate, GFR) as a result of ﬁltration [32] followed by capture by
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sosomes. Endocytosis of NGAL-Scn from the apical (luminal) membrane
is themost likely pathway of NGAL-Scn trafﬁc because it appeared in the
urinewhen the apicalmegalin receptorwasdeleted. Biacore based bind-
ing studies conﬁrmed a direct interaction betweenNGAL-Scn andmega-
lin fragments [33], consistent with capture of NGAL-Scn from the
glomerular ﬁltrate rather than from the basolateral (blood) side.
Similar to serum, urine contains approximately 20 ng/ml NGAL-Scn at
steady state. The origin of this protein is not clear, but some of it may
derive from serum NGAL-Scn (“sNGAL-Scn”) that bypasses capture in
the proximal tubule (approximately 1/200 molecules). Alternatively,
NGAL-Scn might derive from neutrophils or even from bladder epithelia.
However, given the data discussed below, it is most likely that urinary
NGAL-Scn (“uNGAL-Scn”) derives from a low level of expression in the
native kidney at steady state. Indeed, weak in situ RNA reactivity can be
seen in the collecting ducts of some kidneys.
3. Ngal-Scn in Kidney Disease
3.1. NGAL-Scn as the biomarker
NGAL-Scn came to the attention of clinical scientists when it was
found to be markedly upregulated by tissue damage [34]. Hence,
NGAL-Scn joins a large number of stress induced proteins, but only in a
few cases have in-depth studies demonstrated a quantitative relationship
between damage and the expression of the protein. The following “proof
of concept studies” demonstrate a tight linkage between stimuli which
initiate kidney damage and the expression of NGAL-Scn protein. Much
of this work was completed in the urinary pool, but we suspect that
similar data will emerge in ongoing evaluations of serum.
3.1.1. Does NGAL-Scn originate from injured nephrons or from bystander
nephrons?
Whole organ studies, including reciprocal cross-transplants between
NGAL knockout and wild type mice have demonstrated that NGAL-Scn
derives from damaged kidneys. For example, when chimeric mice
(consisting of wild type kidneys placed in NGAL knockout bodies) were
treated with ischemia, uNGAL-Scn and sNGAL-Scn were expressed [35].
On the other hand, there was much less uNGAL-Scn when the NGAL
knockout kidneys were placed in wild type mice and subjected to
ischemia (the urinary level essentially remained in the normal range).
A similar conclusion comes from human transplantation studies:
human uNGAL-Scn and sNGAL-Scn were proportional to the rate of
recovery from delayed graft function after transplantation, meaning that
the greater the dysfunction of the allograft, the greater the expression of
NGAL-Scn [36,37], implying that NGAL-Scn derived from the damaged
nephron. Likewise, a chimeric mouse consisting of TLR4 kidneys placed
in null hosts resulted in the brisk expression of NGAL-Scn in response to
LPS, but TLR4 deleted kidneys placed in wild type hosts failed to generate
the protein (Paragas, unpublished). Themost likely interpretation of both
of these experiments is cell- or “nephron”-autonomous responses to
damage i.e. that NGAL-Scn derived from the damaged nephron and in
the case of LPS from kidney epithelia which expressed TLR4. Cell
autonomy was conclusively shown in cells isolated from the medulla of
the kidney: NGAL-Scn was expressed in response to typical stimuli
which trigger renal disease i.e. depletion of ATP [38], exposure to H2O2
[39] or the exposure to bacteria [33]. These data conﬁrm that autono-
mous responses of the nephrons generate the NGAL-Scn protein.
Microscopic analysis provided additional conﬁrmation that damaged
nephron generates NGAL-Scn. The induction of ischemia in one part of
the kidney resulted in NGAL-Scn RNA expression in nephrons throughout
that domain, but not in the adjacent non-ischemic domain. A speciﬁc
temporal pattern was also seen: tubular expression extended in a
cortical-medullary direction after the injury (Fig. 1). In situ hybridization
using a parafﬁn technique localized NGAL-Scn RNA in tubules with mor-
phological evidence of damage including intra-tubular casts. When aselected group of chronic kidney diseases were evaluated, the location
of NGAL-Scn RNA also corresponded to sites of tubular disease. An animal
model of HIV Associated Nephropathy [40] demonstrated NGAL-Scn ex-
pression in medullary microcysts in late stages of renal failure. In fact,
NGAL-Scn was expressed at levels far in excess of any other gene that
has been previously associatedwith hypoxia, ischemia and renal damage.
Similarly, lining epithelia of Polycystic Kidney Disease [41,42] expressed
NGAL-Scn at levels higher than most other kidney expressed markers of
tissue damage. These data show that the damaged tubule generates
uNGAL-Scn and sNGAL-Scn.
3.1.2. Does the transcriptional response of the kidney parallel NGAL-Scn
in serum and urine, and is this response a reﬂection of the intensity of
the inciting stimulus?
To investigate the quantitative relationships between the expression
of NGAL-Scn in the kidney and the amount of NGAL-Scn protein in the
urine, we created a bioluminescent mouse by placing Luciferase2-
mCherry reporters in the lipocalin2 locus [33]. Luciferase2 expression,
which we designated “kidney NGAL-Scn” was proportional to the dose
of ischemia or the dose of LPS. In addition, kidney luminescence paralleled
the amount of NGAL-Scn protein appearing in the urine in a
dose-responsive fashion. Related ﬁndings come from human studies
of unilateral vs bilateral urinary obstruction [43], as well as studies of
patients entering emergency departments where acute kidney injury
was quantiﬁed by the graded “R-I-F-L” [44,45] or “AKIN” stages [46].
In these cases, NGAL-Scn responded in a quantitative and dose depen-
dent fashion (bilateral renal obstruction induced twice the level of
unilateral disease; higher RIFL or AKIN designations induced pro-
gressively greater amounts of NGAL-Scn). Moreover the kinetics of
NGAL-Luc2 and uNGAL-Scn protein were nearly identical in the onset
of expression, the peak of expression and in the termination of expres-
sion. Taken together, these data show that dose of damage generates a
graded NGAL-Scn response in kidney and, in turn, in urine.
Mori et al. suggested that the disruption of the megalin dependent
endocytic system in the damaged kidney could theoretically result in
a failure to capture sNGAL-Scn from the ﬁltrate, and consequently en-
hance the appearance of uNGAL-Scn [47]. While still reﬂecting neph-
ron damage, this result would differ mechanistically from data
obtained with the NGAL-Luc2-mC mouse. The former reﬂects damage
to a segment of the nephron (the proximal tubule) that does not nor-
mally synthesize NGAL-Scn, while the latter reﬂects distal tubular
synthesis and secretion into the urinary tract. We suspect that proxi-
mal tubule bypass is most likely active in chronic kidney diseases, but
perhaps is self limited in AKI where the GFR falls in the damaged neph-
ron (by deﬁnition). In addition, coordination between NGAL-Luc2 and
uNGAL-Scn and the data from the cross-transplantation experiments
(above) argue in favor of intra-renal synthesis and secretion as a dom-
inant, but perhaps not the sole mechanism of uNGAL-Scn accumulation
(escape from the proximal tubule being the second mechanism).
3.1.3. Does the appearance of NGAL-Scn temporally correlate with the in-
citing stimulus and is its expression reversible?
Kidney Luc2-mCherry and uNGAL-Scn both demonstrated rapid and
reversible responses to ischemia. Data in mice were similar to the
responses of children undergoing surgery and neonates suffering clearly
timed stimuli such as sepsis [42,48,49]; both Luc2-mCherry and NGAL-
Scn protein appeared in blood and urine within 3 h after initiation of
the stimulus and reversed when the stimulus was removed. The rapidity
of the transcription and secretion into the urine differs from other urinary
proteins but the speciﬁc cellular mechanisms that govern NGAL-Scn
secretion have not been characterized.
The reversibility of NGAL-Scn expression can be used to follow the
actions of medications which suppress AKI including HCO3 and
fenoldapam [50,51] in humans, CO donors and PARP inhibitors in
mice [52], and antibiotics in cell models.
Fig. 1. In situ hybridization of NGAL-Scn in the mouse kidney after ischemia–reperfu-
sion injury. Note the expression of NGAL-Scn in short cortical tubules by 6 h and
throughout the TALH and collecting ducts at a later time point.
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Many studies have shown that the presence of either serum or urine
NGAL-Scn anticipates a severe course for the patient in hospital, including
the need for dialysis and the possibility of death (NGAL-Scn at the time of
presentation to the hospital presages 3–20 fold increased probability). In
a metaanalysis, Haase, Bellomo showed that NGAL-Scn+ patients had
more severe illnesses [53] than did the NGAL-Scn− patients and Hall et
al. [54] showed that NGAL-Scn predicted poor outcomes. Ralib, and
Endre et al. found that the daily amount of NGAL-Scn excretion correlated
with the severity of outcomes [44] and NGAL-Scn at the time of discharge
from the hospital presaged return to the hospital with clinically signiﬁ-
cant events [55]. In fact, patients who would otherwise have been over-
looked in the emergency department because of apparently normal
kidney function tests are at risk for rapidly progressive renal failure in
the case that NGAL-Scn is expressed.
3.1.5. What is the role of NGAL-Scn in renal injuries?
As described in detail below, the canonical role of NGAL-Scn is to se-
quester bacteria derived iron-binding catecholate siderophores, particu-
larly enterochelin (Ent). Crystallography and ﬂuorescence quenching
techniques demonstrated that NGAL-Scn binds Ent with high afﬁnity
extending over a broad range of biological pHs [72]. In vivo, the deletion
of the NGAL-Scn gene led to increased mortality when the knockout
mice were subjected to lab strains of bacteria [77]. Data relevant to the
kidney is also now emerging. NGAL-Scn knockout mice cannot defend
themselves against urogenital infections (Paragas et al., unpublished).
Hence, NGAL-Scn is a directed response to infectious damage and conse-
quentlymight also serve as a prophylactic in aseptic injury. On the other
hand, NGAL-Scn may have a related function in aseptic injury such as
scavenging iron with the metabolite catechol (discussed below and
Summary and future experiments). It is also possible that NGAL-Scn
plays a role which is not related to iron chelation per se.We initially iso-
lated this protein by chromatography and a bioassaywhichdemonstrat-
ed the growth and development of embryonic kidney cells [56]. Recent
data from knockout mice also suggested a growth effect, because when
damaged by chronic kidney disease, the knockout mice demonstrated
reduced levels of epithelial proliferation [57]. Further analysis of these
phenotypes may be achieved using experimental forms of NGAL-Scn
which can trafﬁc into the kidney tubule to inhibit bacterial growth, or
to scavenge iron, or to induce epithelial growth.
3.1.6. Are characteristics of NGAL-Scn conserved across different populations
and animal models?
In all models of human and mouse kidney diseases, the NGAL-Scn
“monomer” or full length gene product is found in serum and in urine.
In addition, the majority of the NGAL-Scn protein induced by acute
renal failure in humans and in mice was a monomer. However, humanNGAL-Scn contains an unpaired cysteine and can form not only mono-
mers, but also dimers and hetero-multimers. These “high molecular
forms” are found in chronic kidney diseases but not in acute kidney inju-
ry; their presence suggests either different cellular origins of the protein
or variations in the metabolism of extracellular NGAL-Scn. For example,
the dimer of human NGAL-Scn may arise from neutrophils [58] due to
long storage of the protein in the environment of a neutrophil granule
compared to the rapid secretion of NGAL-Scn monomer from epithelia.
High molecular weight NGAL-Scn species also include cross linkage to
transport proteins such as polymeric Ig receptors. These data are impor-
tant because they suggest that the synthesis, trafﬁcking andmetabolism
of “biomarkers” should be studied in clinical samples especially when
the protein is known to be subject to proteolytic processing including
Kim1 and Cyr61 and when the subject has chronic kidney disease.
Hence, while the expression and functions of NGAL-Scn are likely to
be conserved across man and mouse, gene expression (the monomer)
should be separately analyzed from protein metabolism (additional
post-translational forms). These data are crucial in the analysis of
chronic tissue injury because the speciﬁc form that is associated with
epithelial injury (i.e. tubulointerstitial disease) must be the target of fu-
ture epidemiological investigations [44].
4. Signiﬁcance of NGAL-Scn expression data in clinical medicine
The intrinsic characteristics of NGAL-Scn listed above suggest that its
measurement should be instituted in the diagnosis of tissue injury in
human and in animal models [59,60]. In addition, the dose dependent
and reversible characteristics of NGAL-Scn expression mean that it is
useful to identify therapies that reverse the illness. In contrast, the rise
in serum creatinine (sCr), a measure of functional deﬁciency rather
than tissue damage, might be quite delayed in elderly patients with re-
duced muscle mass (creatinine derives from muscle). Also sCr levels
may be elevated even in the absence of nephron damage as a result of
normal functional changes, a condition which is classically called “pre-
renal AKI” [61–66]. Similar problems apply to the evaluation of chronic
kidney disease. While uNGAL-Scn correlates with the severity of tubulo-
interstitial disease [44], which is the most important pathologic ﬁnding
linked to CKD prognosis [67–70], sCr does not correlate well. Moreover
there is a poor relationship between renal clearance [71] and sCr
[72,73], and in 20% of patients with CKD [74] the relationship of [sCr]−1
and disease progression does not hold at all [75]. Taken together these
data illustrate that the diagnosis of renal tissue injury requires a single
measurement of NGAL-Scn for its analysis, whereas multiple measure-
ments of sCr separated in time are required to measure and characterize
functional deﬁciencies.
5. NGAL-Scn binds co-factors which bind iron
5.1. Siderophores
A breakthrough in the understanding of the prominence of NGAL-
Scn in kidney tissue injury was found in bacterially cloned NGAL-Scn
by R. Strong and colleagues. NGAL-Scn is a member of the lipocalin su-
perfamily which encodes a series of proteins that bind and transport
small organic ligands within their internal calyx (Fig. 2). The lipocalin
super family proteins bind a number of ligands: retinoids bind retinal
binding protein, purpurin and rat epididymal RBP; pheromones bind
major urinary binding proteins; colorants bind astaxanthin, and heme
binds nitrophorins and α1-microglobulin. Goetz et al. [76,77] cloned
NGAL-Scn inGram− bacteria and identiﬁed a bacterial compound called
enterochelin (Ent) bound within the protein's calyx. Ent is an organic
molecule that bacteria utilize to capture iron from the extracellular
media. It is composed of three 2,3 dihydroxybenzoates (catechol-
carboxylic acids) linked by a tri-serine lactone backbone [78] so that
its 6 hydroxyl groups form a “hexadentate” co-ordinate of ferric iron.
R. Strong identiﬁed 3 positively charged amino acids in the base of the
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with Ent's catecholate rings, positioning their 6 hydroxyl groups to in-
teract with iron. The amino acids are critical because their mutation di-
minished Ent:Fe binding. Complexes of NGAL-Scn with Ent:Fe (NGAL-
Scn:Ent:Fe) could form in the bloodstream [79] followed by their
rapid clearance by macrophages in liver and spleen and by ﬁltration
and tubular destruction in the kidney. Fe delivery to the proximal tubule
by NGAL-Scn:Ent:Fe could be visualized using 55Fe and radioautogra-
phy. The pathway depended on megalin, since modiﬁcation of megalin
recognition resulted in the appearance of Fe in urine [75]. Hence, the
binding of Ent to NGAL-Scn not only sequestered the siderophore but
resulted in its clearance in the kidney. Because sNGAL-Scn levels can
rise 100 fold to >2000 ng/ml, as much as 300–400 mg NGAL-Scn/24 h,
containing nearly 1 mg of iron can theoretically trafﬁc to the kidney
for clearance and recycling, provided that Ent is fully saturated and
glomerular ﬁltration is maintained.
The interaction of Ent with NGAL-Scn directly blocked the capture of
iron by bacteria: NGAL-Scn delayed bacterial growth, but an oversupply
of iron or the expression of siderophores [80] which do not recognize
NGAL-Scn, rescued bacterial growth. Consistently, the deletion of NGAL-
Scn by homologous recombination accelerated the growth of Ent depen-
dent bacteria, resulting in sepsis and heightened mortality [81,82]. To-
gether, these data describe an interaction of mammalian NGAL-Scn
protein with a bacterial product (Ent), and the subsequent clearance of
NGAL-Scn:Ent:Fe by the proximal tubule.
It is likely that observations from systemic sepsiswill also apply to the
abundant NGAL-Scn expression within the urinary system, with a num-
ber of important caveats. uNGAL-Scn was signiﬁcantly elevated by com-
munity acquired Gram− urinary infections according to a post-hoc
analysis of patients in emergency departments [42] and other published
cohorts [83,84]. Uropathogenic E. coli were the overwhelming culprits
(70–95% of the cases) and most of these bacteria relied on catecholate-
siderophores to capture iron [85,86] suggesting that NGAL-Scn should
play a critical role in urinary defense. However, NGAL-Scn has been
best characterized with E. coli sHB101 and H9049 which depend solely
on Ent, whereas urinary bacteria potentially have multiple mechanisms
of iron capture such as Salmochelin (Iro), Salmonella iron transport
(Sit), Aerobactin (iutA), and Hemin uptake (Chu), which are NGAL-Scn
resistant, meaning that direct tests of urinary inhibition are required. In
addition, the sources of uNGAL-Scn could be more complex than kidney
ischemia, because both bladder and kidney epithelia may be involved in
the response to urinary bacteria [87]. There are also many apparent dif-
ferences between known urinary antimicrobial peptides and NGAL-Scn
which require further analysis. For example, unlike thewell known anti-
microbial proteins [88–90] the cathelicidins (hCAMP, mCRAMP), theKd=0.4nM
Fig. 2. Bacterial Enterochelin is composed of a triserine lactone backbone which coordinates
enterochelin complex binds the calyx of the lipocalin. The active site of NGAL-Scn is compose
K is lysine). The binding is pH insensitive.
Molecular models courtesy of R. K. Strong, Fred Hutchinson Cancer Research Center, Seattledefensins (HBD1 [91,92]), Tamm–Horsfall [93–97] and Lactoferrin [92],
which are expressed constitutively, uNGAL-Scn is not likely to play a
large role at steady state because it is expressed only at very low levels
(20 ng/ml). In addition, while many of these proteins are modulated
only to a small degree by infections (cathelicidin by 3–8 fold; THP and
lactoferrin are not stimulated by infections [84,98–101] and the AMPs
and lactoferrin remain in the low ng/ml range even after stimulation),
NGAL-Scn was intensively upregulated by signiﬁcant infections (Fig. 3)
[102–106] as well as aseptic stimuli. Consequently the mechanisms of
expression and induction apparently differ between NGAL-Scn and
other antimicrobial peptides even though NGAL-Scn originates from
the same cells as many of these proteins. Also additional analysis of
the molecular characteristics of the NGAL-Scn:Ent interaction is re-
quired to determine whether Ent can be chelated in the harsh environ-
ment of the distal urinary tract (pH4.5; osmolarity 1200 mOsm/l; high
concentrations of urea). It is known that similar to other urinary de-
fenses (Defensin HB1 is active at pH5.5; lactoferrin is active at pH 3.0)
NGAL-Scn:Ent:Fe binding is unusually pH insensitive.
In sum, human andmouse studies have shown that NGAL-Scn is in-
tensively upregulated by signiﬁcant infections that impact the kidney
(200–20,000 ng/ml, Fig. 3). For example, patients entering emergency
rooms demonstrated a linkage between spontaneous, community-
acquired sepsis and uNGAL-Scn expression [62]. In neonates suspected
of sepsis only those neonateswhowere truly infected (i.e. blood cultures
later identiﬁed a pathogen) expressed high levels of uNGAL-Scn, but
those neonates who were not infected (i.e. blood cultures were sterile
or pathogen free) did not express uNGAL-Scn [77,102,107]. Consistent-
ly, cecal ligation and puncture models produced a 531 fold increase in
kidney NGAL-Scn (Paragas and Barasch unpublished). Together, these
data imply that the release of NGAL-Scn into the urinary system is a
major response of the kidney to systemic infection and potentially
local urogenital infection as well.
5.2. Extended function: catechol:iron?
Structural analyses by Strong and co-workers supported the idea that
NGAL-Scn might bind additional ligands. First, Ent failed to ﬁll the NGAL-
Scn calyx, indicating that additional ligands are possible [73]. Second,
NGAL-Scn had at least one additional ligand, a siderophore from
mycobacteria called carboxymycobactin, which is structurally dissimilar
to Ent. Third, a related member of the lipocalin superfamily, lipocalin1,
can accommodate a variety of siderophores [108]. Fourth, while Ent is
not synthesized bymammalian cells, it is a composite ofwell known func-
tional groups such as hydroxybenzoates and hydroxybenzenes which are
found in mammalian serum and urine. These data infer that NGAL-ScnKd=10-49M     Fe Ga Plutonium
three catecholate groups to form a hexadentate site that ligates a single iron atom. Iron–
d of three positively charged amino acids (R81, K125 and K134, where R is arginine and
.
Fig. 3. NGAL-Scn-Luciferase2 (B) and NGAL-Scn RNA (C) expression detected after a
dose of Lipid A. Note the kidney (white circle) and diffuse expression of NGAL-Scn-
Luc2 (B) after the introduction of LipidA. (A) The same mouse before treatment. (C) In-
tercalated cells of the collecting ducts (alternating blue cells) respond to Lipid A and
express NGAL-Scn RNA.
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that these ligands may derive from a variety of sources. Nonetheless, to
date, few candidates have been proposed.
Given the extensive expression of NGAL-Scn in rodent and human
urine subjected to either septic or aseptic renal damage, we used
urine as a source of ligands. First, a paper chromatography assay dem-
onstrated that while 55Fe3+ precipitated in water, the addition of low
molecular weight ﬁltered urine or candidate urinary compounds sol-
ubilized 55Fe3+. Also, their addition to a mixture of NGAL-Scn and
55Fe3+ resulted in stable complexes similar to the addition of Ent.
The urinary compounds that contained the dihydroxybenzene (cate-
chol) functional group demonstrated saturation of NGAL-Scn (as
measured by iron retention), and competition with a 50 fold excess
of Ent:Fe3+ suggested that these compounds potentially occupy the
same sites in the NGAL-Scn calyx as Ent. Simple catechol (1,2-
dihydroxybenzene), pyrogallol (1,2,3-trihydroxybenzene), and 3- or
4-methyl catechol were the most active compounds and were stable
during 20 h of H-NMR inspection. Using ﬂuorescence quenching and
other spectroscopic techniques [72] and structural studies, Strong and
Raymond found that the catechols could add to the calyx in a stepwise
fashion (bis-catechol:Fe3+ ﬁrst, followed by the recruitment of a third
catechol to form tris-catechol:Fe3+) resulting in hexadentate coordina-
tion of iron. Most interestingly, catechol had a poor afﬁnity for NGAL-
Scn but in the presence of iron, the complex formed in the calyx at
much higher afﬁnity (2.1 nM and 0.4 nM). The catechols located at the
same site where Ent bound (between the side-chains of residues K125
and K134), explaining their competition [109]. These data contrast
with two other publications suggesting that norepinephrine (a 3,4
dihydroxycatechol) [110] and the polyphenol 2,5 dihydroxybenzoic
acid can serve as NGAL-Scn ligands for iron [111]. Norepinephrine
might have some NGAL-Scn iron binding activity (50 nM) but it is very
reduced compared to 2,3 dihydroxy-catechols, and2,5 dihydroxybenzoic
acid lacks the iron-coordinated ortho-diol needed for strong chelation at
neutral pH.
NGAL-Scn:catechol:Fe complex could form in mice from its com-
ponent parts and quench the reactivity of catechol mediated Fe3+ re-
duction, and H2O2 mediated oxidation. The complex was stable for
travel to the kidney and liver and bone marrow. This was particularly
evident in the kidney, where the complex could be visualized at the
apical membrane of the proximal tubule by radioautography. Its
iron was likely to be recovered during the process of endocytosis in
acidic endosomes of the proximal cell, because unlike NGAL-Scn:
Ent, some catechols are pH sensitive (catechol>pyrogallol) [112].
This can be modeled in kidney cell lines expressing megalin where
iron capture can be measured. In contrast to these data, transferrin-
55Fe demonstrated much less targeting of the kidney.Catechol was ﬁrst identiﬁed by von Euler. While difﬁcult to mea-
sure because of oxidation upon storage, catechol (up to 150 μM)
[113–117] and 4-methylcatechol (30 μM), and pyrogallol (500 μM)
[109,118] are known to be abundant in the urogenital system. The
majority of the catechols are sulfated and deactivated and this may
take place in the kidney before excretion [119] (free catechols consti-
tute 3–5% of total or 1–5 μM) [120]. However, the exact origin and
metabolism of these molecules require further testing, but dietary
plant quinic, shikimic [121] and 3,4-dihydroxybenzoic acids
[117,122] and related hydroxybenzenes [109,114] or tyrosine metab-
olism to phenol may be their sources. It appears that enteric microor-
ganisms participate at one or more steps of these pathways because
sterilization of the gut reduced catechol excretion [123].
6. Summary and future experiments
NGAL-Scn is a rapid response gene whose expression is driven in a
dose dependent manner by stimuli which generally induce tissue
damage [42,62,75,124]. Its abundance at both the RNA and at the
protein level have intrigued clinical scientists who have conﬁrmed
that its expression and its abundance reﬂects toxic stimulation just
hours before gene expression. The rapidity and the intensity of its
expression have been useful for identifying patients at particular
risk for the onset or progression of kidney dysfunction, and for serious
medical complications (dialysis, death). These basic clinical observa-
tions have been reproduced in many patient populations and animal
models. Given that many stimuli activate NGAL-Scn, the most important
next experiment is to determine the mechanism of signaling from clini-
cally relevant stimuli to cells of the distal kidney. These experimentsmay
come from further patient observations of nephrotoxins which target
speciﬁc domains, or from segment speciﬁc methods of nephron damage
as well as studies of the NGAL-Scn promoter.
There are also many unknowns concerning the trafﬁcking of NGAL-
Scn. A serum pool terminates at the proximal tubule megalin receptor,
but an additional receptor 24p3R has been proposed to participate in
NGAL-Scn capture as well [125,126]. It will be exciting to see if its ex-
pression is important for recycling of NGAL-Scn ligands at the level of
the proximal tubule or whether 24p3R is a highly unusual component
of a protein recovery system in the distal nephron. Our data also suggest
that the urinary pool derives mostly from tubular cells of TALH and col-
lecting ducts but protein secretion from the nephron is notwell studied.
How NGAL-Scn trafﬁcs apically or basolaterally or both is relevant for
our understanding of the clinical data as well as to identify cellular
targeting mechanisms in nephron cells. These mechanisms are of par-
ticular interest in the intercalated cell which undergo reversals of pro-
tein polarity to achieve acid–base homeostasis [127].
Most importantly, there has not been an adequate explanation for
the abundant expression of serum NGAL-Scn in different kidney dis-
eases. Among the many possible explanations (see below), bacteriosta-
sis has the greatest support from structure–function data and from
NGAL-Scn knockout data. However what happens to the siderophore
complex upon clearance in the proximal tubule remains to be seen.
One paper indicates that Ent itself induces cytokine expression [128],
but it is not knownwhether trafﬁcking of NGAL-Scn:Ent to the proximal
tubule has this property; this type of signaling would be a novel mecha-
nism of inducing a renal response to systemic infection.
Bacteriostasis is also the most likely role of urinary NGAL-Scn, but
it remains to be seen if typical urinary pathogens are sensitive to
NGAL-Scn. Also, while systemic sepsis can activate NGAL-Scn expres-
sion through TLR expression, the mechanism of NGAL-Scn induction
in the urogenital system is not fully known, and may involve novel
TLR11 [129] or other receptors.
Given that kidney NGAL-Scn is abundantly expressed in aseptic in-
jury, it has also remained unclear whether NGAL-Scn plays a “prophy-
lactic” role limiting the eventuality that the damaged kidney might be
colonized by ascending bacteria or whether NGAL-Scn has additional
1456 N. Paragas et al. / Biochimica et Biophysica Acta 1823 (2012) 1451–1458activities, such chelation of catechol or its family members when iron
is released from damaged cells. Catechol can mobilize Fe3+ from
other proteins [130] and the catechol:Fe complex may then partici-
pate in iron recycling that stimulates the Fenton reaction [131,132].
In contrast, ligation of catechol:iron within NGAL-Scn calyx may per-
mit transport and excretion of catechol:iron in a less reactive form.
Consequently, targeting of the kidney by both catechol and NGAL-
Scn might clear catechol and iron, as well as Ent and iron [75], remov-
ing potential iron donors for microbes both at the level of ﬁltration
and in the distal nephron. This idea is in principle similar to the pro-
posal of Jones and Cerami et al. [133] who found that low molecular
weight iron carriers in mammalian organs can donate iron to mi-
crobes. Further testing of these speculative hypotheses should in-
clude isolation of NGAL-Scn complexes from urine or serum to
examine occupancy of the calyx, measurement of redox damage in
NGAL-Scn knockout mice and oral antibiotic treatment and dietary
restrictions to decrease catechol metabolites. It should also be possi-
ble to create forms of NGAL-Scn that retarget iron from the proximal
tubule to the urine as a test of the role of NGAL-Scn as an iron scaven-
ger in the damaged nephron.
Finally, it should be pointed out that many groups have shown
that NGAL-Scn is a growth regulator. We initially utilized the devel-
opment of rat kidney progenitors to purify growth factors, identifying
NGAL-Scn. A number of other groups have also ascribed epithelial
growth to NGAL-Scn [134] including in kidney epithelia [135]. In con-
trast, there are reports that the withdrawal of growth factors from
hematopoeitic cells resulted in NGAL-Scn expression followed by ap-
optosis [136]. A similar correlation was documented in the involuting
breast and the post-partum uterus [137–139] where NGAL-Scn was
expressed during the reabsorption phase. Likewise, some authors
have found that NGAL-Scn is stimulated by pro-apoptotic factors
[140] and that it directly induces apoptosis [132,141] in myeloid
and early erythroid progenitors and in the kidney glomerulus [142],
while other authors believe that NGAL-Scn, expressed during apopto-
sis, has a survival activity, because knockdown of NGAL-Scn expres-
sion enhanced apoptosis [136]. Taken together these data suggest
that NGAL-Scn has growth activity that is active in the kidney, but
its mechanism remains unclear. Resolution of these ﬁndings must
await conﬁrmation of the proposed receptor 24p3R or identiﬁcation
of additional novel receptors and their signaling mechanisms as
clues to growth effects. However, at this time, siderophore chelation
and potentially iron scavenging and trafﬁcking remain the most in-
vestigated activities of NGAL-Scn.References
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